Reverie Labs
Reverie Labs used machine learning to design cancer drugs that could cross into the brain. It is no longer operating.
Overview
Reverie Labs was a Cambridge, Massachusetts drug discovery company that built machine-learning models for small-molecule design and applied them to brain-penetrant kinase inhibitors for cancers with central nervous system involvement. It grew to roughly 30 people and ran discovery partnerships before the YC directory marked it inactive; its website was offline when checked. Recorded as wound down; no acquirer is named because none was found in a primary source.
Funding
All startupsPages like this
not linked directly; found by shared links- CompanyHarmonic Discovery
Shares Y Combinator, AI-driven drug & target discovery, Small-molecule kinase inhibitors and the tag yc.
- CompanyResistanceBio (Viosera Therapeutics)
Shares Y Combinator, AI-driven drug & target discovery and the tag yc.
- CompanySerinus Biosciences
Shares Y Combinator, AI-driven drug & target discovery and the tag yc.
- CompanyAlixia
Shares Y Combinator, Small-molecule kinase inhibitors and the tag yc.
- CompanyVelorum Therapeutics
Shares Y Combinator, Small-molecule kinase inhibitors and the tag yc.
- CompanyBlank Bio
Shares Y Combinator, AI-driven drug & target discovery and the tag yc.
- CompanyAlgen Biotechnologies
Shares Y Combinator, AI-driven drug & target discovery and the tag yc.
- CompanyAltay Therapeutics
Shares Y Combinator, Small-molecule kinase inhibitors and the tag yc.